These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27050021)

  • 81. Excess costs of diabetes in the Aboriginal population of Manitoba, Canada.
    Jacobs P; Blanchard JF; James RC; Depew N
    Can J Public Health; 2000; 91(4):298-301. PubMed ID: 10986790
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Direct economic burden and influencing factors in patients with hepatitis B virus related diseases in Jiangsu, China.
    Zhang H; Chao J; Zhu L; Song L; Li X; Liu P
    Asia Pac J Public Health; 2015 Mar; 27(2 Suppl):41S-8S. PubMed ID: 25416293
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cost of microvascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil.
    Julian GS; Accetturi Pititto LM; Miresashvili N; Broe Honoré J; Lopes Assis Coelho RC; Campos D
    J Med Econ; 2021; 24(1):1002-1010. PubMed ID: 34344240
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The financial and health burden of diabetic ambulatory care sensitive hospitalisations in Mexico.
    Lugo-Palacios DG; Cairns J
    Salud Publica Mex; 2016; 58(1):33-40. PubMed ID: 26879505
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Measuring the burden of preventable diabetic hospitalisations in the Mexican Institute of Social Security (IMSS).
    Lugo-Palacios DG; Cairns J; Masetto C
    BMC Health Serv Res; 2016 Aug; 16():333. PubMed ID: 27484124
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Incremental healthcare expenditure attributable to diabetes mellitus: A cost of illness study in Tasmania, Australia.
    Dinh NTT; de Graaff B; Campbell JA; Jose MD; Burgess J; Saunder T; Kitsos A; Wiggins N; Palmer AJ
    Diabet Med; 2022 Jun; 39(6):e14817. PubMed ID: 35181930
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Reply to commentary on costs of diabetes and its complications in Poland.
    Leśniowska J
    Eur J Health Econ; 2015 Mar; 16(2):227. PubMed ID: 25487550
    [No Abstract]   [Full Text] [Related]  

  • 88. The role of cost-effectiveness analysis and health insurance in diabetes care.
    Songer TJ
    Diabetes Res Clin Pract; 2001 Nov; 54 Suppl 1():S7-11. PubMed ID: 11580963
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States.
    Ozawa S; Portnoy A; Getaneh H; Clark S; Knoll M; Bishai D; Yang HK; Patwardhan PD
    Health Aff (Millwood); 2016 Nov; 35(11):2124-2132. PubMed ID: 27733424
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Costs for hospitalized patients with diabetes mellitus in China.
    He M; Ma J; Wang D; Yu X
    Asia Pac J Public Health; 2015 Mar; 27(2):NP925-35. PubMed ID: 22743857
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus.
    Reilly ML; Schillie SF; Smith E; Poissant T; Vonderwahl CW; Gerard K; Baumgartner J; Mercedes L; Sweet K; Muleta D; Zaccaro DJ; Klevens RM; Murphy TV
    J Diabetes Sci Technol; 2012 Jul; 6(4):858-66. PubMed ID: 22920812
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Accountability and utilization of diabetes care from 2005 to 2014 in Taiwan.
    Wang CY; Wu YL; Sheu WH; Tu ST; Hsu CC; Tai TY
    J Formos Med Assoc; 2019 Nov; 118 Suppl 2():S111-S121. PubMed ID: 31590971
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Financial requirements for the treatment of diabetes in Latin America: implications for the health system and for patients in Mexico.
    Arredondo A; de Icaza E
    Diabetologia; 2009 Aug; 52(8):1693-5. PubMed ID: 19504083
    [No Abstract]   [Full Text] [Related]  

  • 94. Cost of Illness of Chronic Hepatitis B Infection in Vietnam.
    Tu HAT; Woerdenbag HJ; Riewpaiboon A; Kane S; Le DM; Postma MJ; Li SC
    Value Health Reg Issues; 2012 May; 1(1):23-28. PubMed ID: 29702821
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Analysis of influencing factors of economic burden and medical service utilization of diabetic patients in China.
    Chen C; Song J; Xu X; Zhou L; Wang Y; Chen H
    PLoS One; 2020; 15(10):e0239844. PubMed ID: 33126237
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Commentary to: Costs of diabetes and its complications in Poland.
    Fayaz-Bakhsh A; Sarvari Mehrabad R
    Eur J Health Econ; 2015 Mar; 16(2):225-6. PubMed ID: 25355296
    [No Abstract]   [Full Text] [Related]  

  • 97. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy.
    Barquera S; Campos-Nonato I; Aguilar-Salinas C; Lopez-Ridaura R; Arredondo A; Rivera-Dommarco J
    Global Health; 2013 Feb; 9():3. PubMed ID: 23374611
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Diabetes mellitus and the St Vincent Declaration. The economic implications.
    Leese B
    Pharmacoeconomics; 1995 Apr; 7(4):292-307. PubMed ID: 10155319
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Incremental Healthcare Costs of Diabetes Mellitus in a Middle-Income Country Using Administrative Healthcare Data.
    Castro-Villarreal S; Miksi S; Beltrán-Ostos A; Valencia CF
    Value Health Reg Issues; 2024 Sep; 43():100992. PubMed ID: 38714097
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A phase of diabetes care at the verge of paradigm shift.
    Yang WS
    J Formos Med Assoc; 2019 Nov; 118 Suppl 2():S63-S65. PubMed ID: 31564386
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.